SMFRW News and Press, Sema4 Holdings Corp. Warrant From 04/06/22

STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform, Centrellis ® , has earned Certified status for information security by the Heal...

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY recently publish...

- The REPRESENT Study Will Create One of the Most Diverse and Comprehensive Clinico-genomic Datasets to Uncover and Address Disparities in Cancer Care - Sema4’s Chief Medical Science Officer Will Discuss the Study at the Community Oncology Alliance’s Annual Con...

Sema4 Holdings Corp. (SMFR) Q4 2021 Earnings Conference Call March 14, 2022 4:30 PM ET Company Participants Joel Kaufman - VP Finance & Corporate Development Eric Schadt - Founder and Chief Executive Officer Isaac Ro - Chief Financial Officer Conference Call Participants Brandon Couillard...

The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2021 Q4 earnings call. For further details see: Sema4 Holdings Corp. 2021 Q4 - Results - Earnings Call Presentation

37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiter...

STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2022. Sema4 was ranked as ...

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the...

STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics , a phenomics-driven drug discovery company, today announced a strategic partnership to accelerate t...

STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: BTIG MedTech, Digital Health, Life S...